Status:
COMPLETED
Resveratrol Stimulates Insulin Sensitivity in Subjects With Obesity and Insulin Resistance
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Conditions:
Obesity
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
There is evidence that resveratrol can improve insulin resistance in rodents and humans with obesity and it can also improve muscle mitochondrial content mediated through activation of AMPK. However, ...
Detailed Description
The investigators included 38 participants who met the following inclusion criteria: adults between 20 and 60 years of age with a diagnosis of HOMA-IR index greater than 2.5, and BMI ≥30 and ≤ 40 kg /...
Eligibility Criteria
Inclusion
- Male and female.
- Between 20 and 60 years
- BMI ≥ 30 and ≤ 40 kg/m2
- Presence of insulin resistance (HOMA-IR index ≥ 2.5)
- Willing and able to sign written informed consent prior to trial entry
Exclusion
- Patients with any type of diabetes.
- Patients with kidney disease diagnosed by a medical or with creatinine\> 1.3 mg / dL for men and \> 1.1 mg / dL for women and / or BUN\> 20 mg / dL.
- Patients with acquired diseases that produce obesity and diabetes secondarily.
- Patients who have suffered a cardiovascular event.
- Patients with gastrointestinal diseases.
- Weight loss \> 3 kg in the last 3 months.
- Catabolic diseases such as cancer and acquired immunodeficiency syndrome.
- Pregnancy status.
- Antibiotic consumption 3 months prior to the study.
- Be an undergraduate or graduate student within the Institute.
- Positive smoking.
- Drug treatment:
- Antihypertensive drugs or treatment
- Treatment with hypoglycemic agents or insulin and antidiabetic drugs.
- Treatment with statins, fibrates or other drugs to control dyslipidemia.
- Use of antibiotics in the three months prior to the study.
- Use of steroid drugs, chemotherapy, immunosuppressants, or radiation therapy.
- Anorexigenic or that accelerate weight loss such as sibutramine or orlistat.
- Probiotic, prebiotic or symbiotic supplements.
Key Trial Info
Start Date :
September 15 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT06961279
Start Date
September 15 2013
End Date
December 1 2018
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran
Mexico City, Mexico